Tag Archives: neoadjuvant chemotherapy

Imfinzi Regimen Cuts Recurrence Risk by a Third and Boosts Two-Year Survival in Bladder Cancer

(IN BRIEF) The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) combined with gemcitabine and cisplatin as neoadjuvant therapy, followed by Imfinzi adjuvant monotherapy, for adults with resectable muscle-invasive bladder cancer. This approval is anchored in NIAGARA Phase III trial data … Read the full press release